Wells Fargo
FLGT icon

Wells Fargo’s Fulgent Genetics FLGT Stock Holding History

Wells Fargo’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-300,000
Closed -$5.07M – 7217
2025
Q1 		$5.07M Sell
300,000
-1,000,000
-77% -$17M ﹤0.01% 2401
2024
Q4 		$24M Buy
1,300,000
+300,000
+30% +$5.86M 0.01% 1232
2024
Q3 		$21.7M Hold
1,000,000
– – ﹤0.01% 1247
2024
Q2 		$19.6M Hold
1,000,000
– – ﹤0.01% 1253
2024
Q1 		$21.7M Hold
1,000,000
– – 0.01% 1181
2023
Q4 		$28.9M Buy
+1,000,000
New +$26.8M 0.01% 975

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wells Fargo's FLGT Position: Q1 2026 in Review

Wells Fargo increased its Fulgent Genetics (FLGT) stake by 22% in Q1 2026, buying an estimated $572K and bringing the position to 147,135 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #3154.

Wells Fargo first reported a position in FLGT in Q4 2016 and has held it in 32 quarters since. The position peaked at $6.27M in Q4 2021. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • Wells Fargo held 147,135 shares of Fulgent Genetics worth $2.34M as of Q1 2026.
  • Wells Fargo bought 26,354 Fulgent Genetics shares in Q1 2026, an estimated $572K.
  • Fulgent Genetics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3154 holding.
  • Wells Fargo first reported a position in Fulgent Genetics in Q4 2016 and has held it in 32 quarters since.
  • Wells Fargo's Fulgent Genetics position peaked at $6.27M in Q4 2021.
  • 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.